Table 2.
Proportions of apoptotic DAOY and D283MED cells after treatment with chemotherapy or in combination with IAP inhibitor
| Cell line | Treatment | Apoptosis (%)a | P‐value |
|---|---|---|---|
| DAOY | Control | 6.6 ± 3.2% | |
| LCL161 | 17.2 ± 2.5% | 0.0106 | |
| LBW242 | 22.6 ± 1.2% | 0.0013 | |
| Vincristine | 6.0 ± 2.1% | ||
| Vincristine + LCL161 | 42.1 ± 0.2% | >0.0001 | |
| Vincristine + LBW242 | 51.2 ± 3.8% | >0.0001 | |
| Cisplatin | 13.3 ± 2.4% | ||
| Cisplatin + LCL161 | 34.0 ± 8.0% | 0.0127 | |
| Cisplatin + LBW242 | 54.7 ± 1.0% | >0.0001 | |
| D283MED | Control | 11.3 ± 0.2% | |
| LCL161 | 14.0 ± 0.4% | 0.0005 | |
| LBW242 | 20.1 ± 0.3% | >0.0001 | |
| Vincristine | 34.4 ± 2.4% | ||
| Vincristine + LCL161 | 49.7 ± 2.0% | 0.0011 | |
| Vincristine + LBW242 | 59.0 ± 3.2% | 0.0004 | |
| Cisplatin | 55.3 ± 3.5% | ||
| Cisplatin + LCL161 | 78.7 ± 2.1% | 0.0006 | |
| Cisplatin + LBW242 | 77.3 ± 0.6% | 0.0004 |
a
Apoptosis was detected by Annexin V/PI and apoptotic proportion was quantitated by FACS based on Annexin V‐positive population.